|
Federal Partners Senior Workgroup for Mental Health Transformation
|
Committee, Work group, Advisory group, or Task Force
|
ACF, AoA, AHRQ, CDC, CMS, FDA, HRSA, SAMHSA
|
NIDA, NIMH
|
The workgroup is the direct result of President''s BUSH''s New Freedom Initiative, which included 10 proposals designed to “tear down the barriers that face Americans with disabilities,” This workgroup provides a forum for brainstorming ideas for improving the nation''s mental health. Initiatives are collated, coordinated, streamlined and presented to the interagency steering committee for further discussion and possible implementation.
|
|
Federal Working Group on Bone Diseases
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, OS
|
NIDCR, CSR, NCCAM, NCI, NCATS, NEI, NIA, NIAAA, NIAMS, NIBIB, NICHD, NIDDK, NIEHS, NIMH, NINR, OD
|
Serves to develop and foster collaborative activities among the government agencies in bone diseases.
|
|
Federal Working Group on Dietary Supplements (FWGoDS)
|
Committee, Work group, Advisory group, or Task Force
|
AoA, AHRQ, CDC, FDA
|
OD, CC, CSR, FIC, NCCAM, NCI, NCATS, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM
|
To facilitate communication and collaboration between NIH and its federal partners in several ways: to co-fund research investigations within the NIH, to expand opportunities for research-investigator training, and to strengthen collaborative efforts involving dietary supplement research, education, and communication. The FWGoDS meets twice a year and serves as a means of communication between the Office of Dietary Supplements (ODS) and its federal partners.
|
|
Federal Working Group on International Migration Statistics and Research
|
Committee, Work group, Advisory group, or Task Force
|
ACF, CDC, OS
|
NICHD
|
This working group brings together agencies from across the Executive Branch to share current work and to collaborate on joint projects to advance the federal government''s contribution in the area of international migration.
|
|
FedTel: Cross-Federal Work Group on Telehealth
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, IHS
|
NIBIB, NLM, OD
|
The goal of this work group is to develop a coordinated view of what the Federal government is undertaking in Telehealth, in an effort to identify possible collaboration mechanisms and share lessons learned across multiple agencies. Current topics of emphasis include Telehealth and HIT; Technology, Innovation and Standards; Public Education of Telehealth; and Access to Health Care.
|
|
Filovirus Animal Non-Clinical Group (FANG) Team Charter
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NIAID, CC
|
PURPOSE: The Filovirus Animal Non-Clinical Group (FANG) focuses on the advanced development of Filovirus Medical Countermeasures (MCM), both vaccines and therapeutics. The FANG will focus on the product development tools and other interagency product development (PD) issues relevant to Food and Drug Administration approval of Filovirus MCM.
MISSION: The Portfolio Advisory Committee (PAC), as a standing interagency working group, oversees the FANG. The FANG will develop strategies to address broadly applicable and interagency product development issues relevant to licensure of Filovirus MCM. The FANG will develop consensus recommendations to facilitate standardization of reagents, methods and procedures across multiple agencies and laboratories.
|
|
Fistula First
|
Committee, Work group, Advisory group, or Task Force
|
CMS, HRSA
|
NIDDK
|
The Fistula First Breakthrough Coalition (FFBI) works together with the entire renal community to ensure that every suitable patient will receive the most optimal form of vascular access, which, in most cases, will be a native arteriovenous fistula (AV fistula). The FFBI also focuses on reducing catheter use and vascular access complications. During FY 2010, the National Kidney Disease Education Program collaborated with Fistula First to produce a series of web-based provider and patient educational videos.
|
|
Forum on Child and Family Statistics
|
Committee, Work group, Advisory group, or Task Force
|
ACF, AHRQ, CDC, HRSA, SAMHSA
|
NIMH, NICHD, NIDA
|
The Federal Interagency Forum on Child and Family Statistics, or the Forum, is a working group of Federal agencies that collect, analyze, and report data on issues related to children and families. The Forum''s signature report, America''s Children: Key National Indicators of Well-Being, provides annual updates on the well-being of children and families in the United States across a range of domains.
|
|
Forum on Global Violence Prevention
|
Committee, Work group, Advisory group, or Task Force
|
ACF, CDC, SAMHSA
|
NIDA, NIAAA
|
The IOM''s Forum on Global Violence Prevention works to reduce violence worldwide by promoting research on both protective and risk factors and encouraging evidence-based prevention efforts. The Forum aims to facilitate dialogue and exchange by bringing together experts from all areas of violence prevention, including behavioral scientists, policy makers, criminal justice professionals, social service providers, economists, legal experts, journalists, philanthropists, faith-based organizations, corporate social responsibility officers, among others.
|
|
Frequent Hemodialysis Network (FHN) Clinical Trials
|
Research Initiative
|
CMS
|
NIDDK
|
The Frequent Hemodialysis Network (FHN) is testing two different approaches to increasing dialysis at Clinical Centers in the U.S. and Canada. The FHN Daily Trial is a randomized controlled trial that randomizes 250 subjects to either conventional hemodialysis delivered for at least 2.5 hours, 3 days per week, or to more frequent hemodialysis delivered for 1.5 – 2.75 hours, 6 days per week. Subjects will be followed for 12 months. The current FHN Nocturnal Trial randomizes 250 subjects to home conventional hemodialysis delivered three days per week or to nocturnal home hemodialysis given six times per week that provides a standardized Kt/V equal to or greater than 4 and treatment equal to or longer than 6.0 hours. Due to the necessity of training for home dialysis, subjects are followed for 14 months. Two outcomes are being assessed in both trials. The first is a composite measure of change in left ventricular mass or death. The second is a composite of change in the physical health composite of the SF36 or death.
|